Snorx, Inc. Changes Name to Zelegent, Inc.
IRVINE, CA (May 12, 2015) – Snorx, Inc., the developer of an innovative minimally invasive surgical interventional anti-snoring device, today reported that after a re-branding exercise led by branding expert Dean del Sesto and his firm Brevity, Inc., the Company’s Board of Directors has voted to change the name of the company to Zelegent, Inc.
“The ‘Z’ is evocative of sleep. Zelegent rhymes with intelligent and sounds somewhat like elegant,” said Alexander K. Arrow, MD, CFA, Chief Executive Officer, “which fits our mission to create the most elegant, simple-to-use, effective and desirable snoring-corrective surgical tool. Also, the name contains ‘ENT,’” Arrow continued, “like successful ENT companies Acclarent, Entellus, ENTrigue, and Intersect ENT.”
About Zelegent, Inc.
Zelegent, Inc. (formerly Snorx, Inc.), is a medical technology company that is developing, and plans to manufacture and market, innovative tools for physicians who treat sleep disorders. Zelegent was co-founded by two of the world’s leading authorities on sleep disorders, Dr. Yosef P. Krespi who heads the New York Head and Neck Institute Sleep Disorder Center, and Dr. David O. Volpi, founder of the eos sleep Network (formerly the Manhattan Sleep Center). The company’s mission is to develop and commercialize a novel minimally-invasive surgical tool to be used by sleep specialist otolaryngologists to treat snoring by shortening, suspending, and stiffening the patient’s soft palate, the source of most snoring. The Zelegent tool is an investigational device only and is not for sale in the United States.
